PRVA - Privia Health Group, Inc.
ARLINGTON, Va., July 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its second-quarter and six-month periods ended June 30, 2026 before market open on Thursday, August 6, 2026.
CEO Parth Mehrotra sold 121,086 shares directly for a total of ~$2.73 million at an average price of around $22.56 per share across two days ending May 12, 2026. This transaction represented 21.80% of Mehrotra's direct holdings prior to the sale, reducing his direct position to 434,357 shares.
On June 04, 2026, Privia Health Group Inc (PRVA) shares rose 3.4% to a current price of $21.37. Over the past 52 weeks, the stock has traded between $18.77 and
Privia Health Group delivers technology-driven solutions to optimize physician practices and support value-based care nationwide.
Fort Lauderdale, May 28, 2026 (GLOBE NEWSWIRE) -- Cross Keys Capital, LLC, a leading independent investment banking firm providing M&A advisory services to physician group practices and healthcare services companies,is pleased to announce it acted as the exclusive financial advisor to the Neurology Group of Bergen County (“NGBC”) in its partnership with Privia Health. Founded in 1973, the Neurology Group of Bergen County is one of the region's most respected independent neurology practices, serving the communities of Bergen County, New Jersey.
Investors looking for stocks in the Medical Info Systems sector might want to consider either TruBridge (TBRG) or Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?
ARLINGTON, Va., May 27, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA), a national physician enablement company, announced it has signed a definitive agreement to enter the state of New Jersey in partnership with Neurology Group of Bergen County (NGBC), a practice with 25 adult and pediatric clinicians.
Investors interested in Medical Info Systems stocks are likely familiar with TruBridge (TBRG) and Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?
Privia Health Group NASDAQ: PRVA reported a strong first quarter, with executives pointing to double-digit provider growth, a larger value-based care population and margin expansion as signs that the company's operating model continues to scale.
Privia Health Group, Inc. (PRVA) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Privia Health (PRVA) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.03 per share a year ago.
Privia Health Reports First Quarter 2026 Financial Results; Strong First Quarter Performance and Operating Execution; Reiterated Full-Year 2026 Guidance
ARLINGTON, Va., April 08, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its first quarter ended March 31, 2026 before market open on Thursday, May 7, 2026.
JPMorgan Chase and Co. increased its holdings in Privia Health Group, Inc. (NASDAQ: PRVA) by 26.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,709 shares of the company's stock after acquiring an additional 30,845 shares during
ARLINGTON, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated medical groups, collectively Privia Medical Group, has been named a recipient of the 2026 MAP (Measure, Apply, Perform) Award for High Performance in Revenue Cycle, sponsored by the Healthcare Financial Management Association (HFMA).
Privia Health's CFO sold 13,018 direct shares for approximately $283,000 over two days, at an average price of $21.71 per share. The sale represented 5.24% of the CFO's total direct holdings as of the transaction dates.
The average of price targets set by Wall Street analysts indicates a potential upside of 43.4% in Privia Health (PRVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Shares of Privia Health Group, Inc. (NASDAQ: PRVA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the sixteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The
WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rat.